☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
US
Lantern Pharma's LP-184 Gains the US FDA’s Fast-Track Designation to Treat TNBC
December 19, 2024
New Drug Designations - October 2024
November 26, 2024
Fresenius Kabi and Formycon Report the CHMP’s Positive Opinion of Ahzantive/Baiama/FYB203 (Biosimilar, Eylea)
November 18, 2024
Samsung Bioepis Report the CHMP’s Positive Opinion of Obodence & Xbryk (Biosimilar, Prolia & Xgeva)
November 15, 2024
ARTHEx Biotech Secures the US FDA’s Rare Pediatric Designation (RPD) to ATX-01 for Treating Myotonic Dystrophy Type 1 (DM1)
November 7, 2024
Shorla Oncology Reports the US FDA’s Expanded Approval of Jylamvo for Pediatric Indications
October 30, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.